Alarming Study Links Obesity and Heavy Drinking to Soaring Liver Disease Rates
Decades of rising heavy drinking and obesity rates have triggered a dramatic surge in preventable liver disease cases, according to new research. The study, published in JAMA Internal Medicine, analysed data representative of over 257 million US adults, revealing that nearly one in ten are both obese and consume alcohol heavily. This dangerous combination significantly elevates their risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease.
The Silent Progression of Liver Damage
Alcohol consumption has long been recognised for its damaging effects on the liver, gradually impairing its ability to filter toxins from the blood—a deterioration that can become life-threatening. Similarly, obesity places substantial strain on the organ, with fat accumulation leading to inflammation and scarring that may result in sepsis. Crucially, whether caused by alcohol or obesity, MASLD often develops silently, meaning many individuals remain unaware of their condition until irreversible liver damage has occurred.
Dr Bryant Shuey, an internal medicine expert at the University of Pittsburgh and lead author of the study, emphasised the urgent need for intervention. "Public health and clinical interventions to mitigate risk factors for this high-risk population are needed to curb rising rates of alcohol-associated liver disease deaths," he stated. Dr Shuey added that preventative efforts should specifically target younger and middle-aged adults, who have a better chance of recovery if the disease is detected early.
Study Methodology and Key Findings
The research team analysed the drinking habits of 45,133 US adults using the 2023 National Survey on Drug Use and Health. Heavy drinking was defined as:
- 15 or more drinks per week for men, or five or more per day
- Exceeding eight drinks weekly for women
Participants with a body mass index (BMI) of 30 or above were classified as obese, following national guidelines. The cohort was divided into five subgroups: obese individuals, heavy drinkers, those with alcohol use disorder, individuals with overlapping heavy drinking and obesity, and those who were both obese and had an alcohol problem.
The findings revealed that young to middle-aged adults were most likely to be both obese and heavy drinkers. Approximately 12% of women aged 26 to 34 fell into this category, with the prevalence of overlapping alcohol-use disorder and obesity also highest among this age group. The trend diminished with age, with only 6% of men aged 65 and older being both obese and consuming more than 15 drinks weekly.
Treatment Strategies and Future Projections
The researchers concluded: "Whilst evidence is limited on concurrent treatment of risky alcohol use and obesity, clinicians should offer interventions that are effective for both conditions, including motivational interviews, cognitive behavioural therapy and pharmacotherapy." They highlighted that weight-loss medications, collectively known as GLP-1 agonists such as Mounjaro and Wegovy, could aid in combating liver disease.
Dr Shuey explained: "Expanding access for patients with co-occurring risky alcohol use and obesity may reduce liver disease burden. Early trials also suggested GLP-1 receptor antagonists may reduce alcohol use among patients with alcohol use disorder. If this finding is confirmed in larger studies, GLP-1s could become a dual therapeutic for risky alcohol use and obesity."
The team cautioned that the actual number of adults at risk might be higher due to underreporting of alcohol use. Latest figures from the Global Burden of Disease study estimate that 1.3 billion people were living with MASLD in 2023. Worldwide, alcohol-associated end-stage liver disease, where the organ is severely damaged, affects more than 23.6 million individuals. This figure is projected to rise to around 1.8 billion over the next 25 years, positioning MASLD as one of the fastest-growing health challenges globally.
Long-Term Risks and Management
Although more cases are now being diagnosed, the overall health impact has remained relatively stable—a trend researchers attribute to earlier detection and improved management slowing disease progression. However, experts warn that long-term risks remain severe. If left undetected and unmanaged, liver disease in any form can advance to cirrhosis, liver failure, and liver cancer, underscoring the critical importance of proactive public health measures and personalised clinical interventions.
